When did Emergent Biosolutions Inc file this DEFA14A?

Emergent Biosolutions Inc (EBS) filed this Additional Proxy Materials (DEFA14A) with the SEC on March 20, 2026. The accession number assigned by EDGAR is 0001367644-26-000034.

What does a DEFA14A disclose?

DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.

What is the key takeaway from this filing?

Consult the filing for more details. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.

Where can I find Emergent Biosolutions Inc's prior proxy statements on EDGAR?

The SEC EDGAR browser lists every DEFA14A Emergent Biosolutions Inc has filed under CIK 1367644, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.

Boardroom Alpha

EBS · Additional Proxy Materials (DEFA14A) · Filed March 20, 2026

Emergent Biosolutions Inc — Additional Proxy Materials (DEFA14A)

Form

DEFA14A

Filed

March 20, 2026

Ticker

EBS

Accession

0001367644-26-000034

Emergent Biosolutions Inc on Boardroom Alpha View on SEC EDGAR

Boardroom Alpha · Filing insights

Consult the filing for more details.

About Emergent Biosolutions Inc

Market cap

$424M

1Y TSR

+34.0%

3Y TSR

+0.8%

Board grade

Sector

Healthcare

CEO

Joseph C Papa

Last annual meeting: Apr 29, 2026 · View full Emergent Biosolutions Inc profile →

Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934 (Amendment No. )


Filed by the Registrant x
Filed by a Party other than the Registrant o
Check the appropriate box:
o			Preliminary Proxy Statement
o			Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2))
o			Definitive Proxy Statement
x			Definitive Additional Materials
o			Soliciting Material under §240.14a‑12


Emergent BioSolutions Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
x	No fee required.
o	Fee computed on table below per Exchange Act Rules 14a‑6(i)(1) and 0‑11.
	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0‑11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
o	Fee paid previously with preliminary materials.
o	Check box if any part of the fee is offset as provided by Exchange Act Rule 0‑11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
	(1)	Amount Previously Paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:
	(4)	Date Filed:

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

See Meeting Forecast Schedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Emergent Biosolutions Inc (EBS)

10-QQuarterly Report
May 1, 2026
8-KCurrent Report
Apr 30, 2026
8-KCurrent Report
Apr 30, 2026
DEFA14AAdditional Proxy Materials
Apr 28, 2026
DEFA14AAdditional Proxy Materials
Apr 27, 2026
DEFA14AAdditional Proxy Materials
Apr 22, 2026
8-KCurrent Report
Apr 17, 2026
DEFA14AAdditional Proxy Materials
Apr 16, 2026
DEFA14AAdditional Proxy Materials
Apr 16, 2026
DEF 14AProxy Statement
Mar 20, 2026
8-KCurrent Report
Mar 3, 2026
10-KAnnual Report
Feb 27, 2026

Continue researching

Reference

Frequently asked questions

When did Emergent Biosolutions Inc file this DEFA14A?: Emergent Biosolutions Inc (EBS) filed this Additional Proxy Materials (DEFA14A) with the SEC on March 20, 2026. The accession number assigned by EDGAR is 0001367644-26-000034.
What does a DEFA14A disclose?: DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?: Consult the filing for more details. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Emergent Biosolutions Inc's prior proxy statements on EDGAR?: The SEC EDGAR browser lists every DEFA14A Emergent Biosolutions Inc has filed under CIK 1367644, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer